New hope for Tough-to-Treat blood cancer
NCT ID NCT06645678
Summary
This study is testing how safe and effective a combination of two new drugs, mezigdomide and elranatamab, is for people with multiple myeloma that has come back or stopped responding to other treatments. The first part of the study will find the best dose, and the second part will see how well the combination works in about 75 participants. The main goal is to see how many patients' cancer shrinks or disappears after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center, University of Ulsan College of Medicine
RECRUITINGSeoul, South Korea
-
Chonnam National University Hwasun Hospital
RECRUITINGHwasun, South Korea
-
National University Hospital (NUH)
RECRUITINGSingapore, Singapore
Contact
-
Samsung Medical Center, Sungkyunkwan University School of Medicine
RECRUITINGSeoul, South Korea
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, South Korea
-
Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea
RECRUITINGSeoul, South Korea
-
Singhealth Duke NUS blood cancer center
RECRUITINGSingapore, Singapore
Contact
Conditions
Explore the condition pages connected to this study.